Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck

Bone

Volumn 35, Issue 1, 2004, Pages 334-342

  Tsangari, Helen ^a   Findlay, David M ^b   Kuliwaba, Julia S ^a   Atkins, Gerald J ^b   Fazzalari, Nicola L ^a,b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Femoral fracture; Human; IL 6; Osteoporosis; RANK mRNA; RANKL OPG; Trabecular bone

Indexed keywords

CALCITONIN RECEPTOR; INTERLEUKIN 11; INTERLEUKIN 6; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTICLE; BONE REMODELING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMUR NECK FRACTURE; FRAGILITY FRACTURE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MICROENVIRONMENT; MOLECULAR MECHANICS; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SAMPLING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TOTAL HIP PROSTHESIS; TRABECULAR BONE;

AGED; AGED, 80 AND OVER; BONE REMODELING; CARRIER PROTEINS; FEMALE; FEMORAL NECK FRACTURES; FEMUR; GLYCOPROTEINS; HUMANS; INTERLEUKIN-11; INTERLEUKIN-6; MALE; MEMBRANE GLYCOPROTEINS; OSTEOCALCIN; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CALCITONIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER;

EID: 2942739081     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.02.006     Document Type: Article

References (71)

1. Ross P.D. Osteoporosis. Frequency, consequences, and risk factors. Arch. Intern. Med. 156:1996;1399-1411
2. Cooper C., Campion G., Melton L.J. III Hip fractures in the elderly: a world-wide projection. Osteoporosis Int. 2:1992;285-289
3. Burger H.G., Dudley E.C., Hopper J.L., Groome N., Guthrie J.R., Green A., et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J. Clin. Endocrinol. Metab. 84:1999;4025-4030
4. Pfeilschifter J., Koditz R., Pfohl M., Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 23:2002;90-119
5. Pacifici R., Brown C., Puscheck E., Friedrich E., Slatopolsky E., Maggio D., et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. U. S. A. 88:1991;5134-5138
6. Jilka R.L., Hangoc G., Girasole G., Passert G., Williams D.C., Abrams J.S., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 257:1992;88-91
7. Bismar H., Diel I., Ziegler R., Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J. Clin. Endocrinol. Metab. 80:1995;3351-3355
8. Passeri G., Girasole G., Jilka R.L., Manolagas S.C. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology. 133:1993;822-828
9. Cantatore F.P., Loverro G., Ingrosso A.M., Lacanna R., Sassanelli E., Selvaggi L., et al. Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin. Rheumatol. 14:1995;157-160
10. Straub R.H., Hense H.W., Andus T., Scholmerich J., Riegger G.A., Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J. Clin. Endocrinol. Metab. 85:2000;1340-1344
11. Scheidt-Nave C., Bismar H., Leidig-Bruckner G., Woitge H., Seibel M.J., Ziegler R., et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J. Clin. Endocrinol. Metab. 86:2001;2032-2042
12. Gregory M.S., Duffner L.A., Faunce D.E., Kovacs E.J. Estrogen mediates the sex difference in post-burn immunosuppression. J. Endocrinol. 164:2000;129-138
13. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 139:1998;4743-4746
14. Ishida A., Fujita N., Kitazawa R., Tsuruo T. Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. J. Biol. Chem. 277:2002;26217-26224
15. Horwood N.J., Kartsogiannis V., Quinn J.M., Romas E., Martin T.J., Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265:1999;144-150
16. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3597-3602
17. Yasuda H., Shima N., Nakagawa N., Mochizuki S.-I., Yano K., Fujise N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 139:1998;1329-1337
18. Takahashi N., Udagawa N., Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256:1999;449-455
19. Hofbauer L.C., Kholsa S., Dunstan C.R., Lacey D.L., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15:2000;2-12
20. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247:1998;610-615
21. Fazzalari N.L., Kuliwaba J.S., Atkins G.J., Forwood M.R., Findlay D.M. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J. Bone Miner. Res. 16:2001;1015-1027
22. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 275:2000;768-775
23. Hofbauer L., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., Riggs L.B. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 140:1999;4367-4370
24. Vidal O.N., Sjogren K., Eriksson B.I., Ljunggren O., Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-1 in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem. Biophys. Res. Commun. 248:1998;696-700
25. Brandstrom H., Bjorkman T., Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem. Biophys. Res. Commun. 280:2001;831-835
26. Srivastava S., Toraldo G., Weitzmann M.N., Cenci S., Ross F.P., Pacifici R. Estrogen decreases osteoclast formation by downregulating receptor activator of NF-kappaB ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276:2001;8836-8840
27. Kanis J.A., Johnell O., Oden A., Jonsson B., De Laet C., Dawson A. Prediction of fracture from low bone mineral density measurements overestimates risk. Bone. 26:2000;387-391
28. Wicks M., Garrett R., Vernon-Roberts B., Fazzalari N.L. Absence of metabolic bone disease in the proximal femur in patients with fracture of the femoral neck. J. Bone Joint Surg. 64:1982;319-322
29. Fazzalari N.L., Darracott J., Vernon-Roberts B. Histomorphometric changes in the trabecular structure of a selected stress region in the femur in patients with osteoarthritis and fracture of the femoral neck. Bone. 6:1985;125-133
30. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159
31. Kuliwaba J.S., Findlay D.M., Atkins G.J., Forwood M.R., Fazzalari N.L. Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. J. Bone Miner. Res. 15:2000;332-341
32. Atkins G.J., Haynes D.R., Graves S.E., Evdokiou A., Hay S., Bouralexis S., et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J. Bone Miner. Res. 15:2000;640-649
33. O'Brien C.A., Dubrij I., Lin S.C., Saylors R.L., Manolagas S.C. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1, 25-dihydroxyvitamin D3 or parathyroid hormone. J. Biol. Chem. 274:1999;19301-19308
34. Romas E., Udagawa N., Zhou H., Tamura T., Saito M., Taga T., et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin-11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J. Exp. Med. 183:1996;2581-2591
35. Shaughnessy S.G., Walton K.J., Deschamps P., Butcher M., Beaudin S.M. Neutralization of interleukin-11 activity decreases osteoclast formation and increases cancellous bone volume in ovariectomized mice. Cytokine. 20:2002;78-85
36. Suda T., Nakamura I., Jimi E., Takahashi N. Regulation of osteoclast function. J. Bone Miner. Res. 12:1997;869-879
37. Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G.D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 144:1990;4226-4230
38. O'Keefe R.J., Teot L.A., Singh D., Puzas J.E., Rosier R.N., Hicks D.G. Osteoclasts constitutively express regulators of bone resorption: an immunohistochemical and in situ hybridization study. Lab. Invest. 76:1997;457-465
39. Roodman G.D. Interleukin-6: an osteotropic factor? J. Bone Miner. Res. 7:1992;475-478
40. Jilka R.L. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone. 23:1998;75-81
41. Lowik C.W., van der Pluijm G., Bloys H., Hoekman K., Bijvoet O.L., Aarden L.A., et al. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Commun. 162:1989;1546-1552
42. Pacifici R. Aging and cytokine production. Calcif. Tissue Int. 65:1999;345-351
43. Hofbauer L.C., Auefelder A.E. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. Mol. Med. 79:2001;243-253
44. Haynes D.R., Crotti T.N., Potter A.E., Loric M., Atkins G.J., Howie D.W., et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J. Bone Joint Surg. Br. 83:2001;902-911
45. Crotti T.N., Smith M.D., Weedon H., Ahern M.J., Findlay D.M., Kraan M., et al. Receptor activator of NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semi-quantitative and quantitative analysis. Ann. Rheum. Dis. 61:2002;1047-1054
46. Siggelkow H., Eidner T., Lehmann G., Viereck V., Raddatz D., Munzel U., et al. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J. Bone Miner. Res. 18:2003;529-538
47. Cao J., Venton L., Sakata T., Halloran B.P. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J. Bone Miner. Res. 18:2003;270-277
48. Martin T.J., Udagawa N. Hormonal regulation of osteoclast function. Trends Endocrinol. Metab. 9(1):1998;6-12
49. Kishimoto T., Akira S., Marazaki N., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 86:1995;1243-1254
50. Manolagas S.C., Bellido T., Jilka R.L. New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130. Int. J. Immunopharmacol. 17:1995;109-116
51. Roodman G.D. Osteoclast function in Paget's disease and multiple myeloma. Bone. 17:1995;S57-S61. [Suppl.]
52. Roodman G.D., Kurihara N., Ohsaki Y., Kukita A., Hosking D., Demulder A., et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J. Clin. Invest. 89:1992;46-52
53. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11:1996;88-95
54. Grey A., Mitnick M.A., Shapses S., Ellison A., Gundberg C., Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption - A clinical research center study. J. Clin. Endocrinol. Metab. 81:1996;3450-3454
55. Lorentzon M., Lorentzon R., Nordstrom P. Interleukin-6 gene polymorphism is related to bone and mineral density during and after puberty in healthy white males: a cross-sectional and longitudinal study. J. Bone Miner. Res. 15:2000;1944-1949
56. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 level, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102:1998;1369-1376
57. Ralston S.H., Russell R.G.G., Gowen M. Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J. Bone Miner. Res. 5:1990;983-988
58. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 25:1999;255-259
59. 2 in human bone marrow stroma cells. Biochem. Biophys. Res. Commun. 247:1998;338-341
60. Hofbauer L.C., Dunstan C.R., Seplsberg T.C., Riggs B.L., Kholsa S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenic protein-2, and cytokines. Biochem. Biophys. Res. Commun. 250:1998;776-781
61. 2+ sensing in the regulation of osteoclastic bone resorption. J. Cell Biol. 142:1998;1347-1356
62. Body J.J., Fernandez G., Lacroix M., Vandenbussche P., Content J. Regulation of lymphocyte calcitonin receptors by interleukin-1 and interleukin-6. Calcif. Tissue Int. 55:1994;109-113
63. Girasole G., Jilka R., Passeri G., Boswell S., Boder G., Williams D., et al. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89:1992;883-891
64. Kishimoto T. The biology of interleukin-6. Blood. 74:1989;1-10
65. Linkhart T., Linkhart S., MacCharles D., Long D., Strong D. Interleukin-6 messenger RNA expression and interleukin-6 protein secretion in cells isolated from normal human bone: regulation by interleukin-1. J. Bone Miner. Res. 6:1991;1285-1294
66. Ahlen J., Andersson S., Mukohyama H., Roth C., Backman A., Conaway H.H., et al. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone. 31:2002;242-251
67. Cappellen D., Luong-Nguyen N.H., Bongiovanni S., Grenet O., Wanke C., Susa M. Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J. Biol. Chem. 1277:2002;21971-21982
68. Kudob O., Sabokbara A., Pococka A., Itonagab I., Fujikawab Y., Athanasou N.A. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 32:2003;1-7
69. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:2000;1481-1488
70. Bell K.L., Loveridge N., Power J., Garrahan N., Meggitt B.F., Reeve J. Regional differences in cortical porosity in the fractured femoral neck. Bone. 24:1999;57-64
71. Miller M., Chin J., Miller S., Fox J. Disparate effects of mild, moderate and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone. 23:1998;257-266